<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) predominates in pediatric patients, whereas diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) is uncommon </plain></SENT>
<SENT sid="1" pm="."><plain>In contrast to adults, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> are treated similarly in children and both entities have superior outcomes in children compared with adults </plain></SENT>
<SENT sid="2" pm="."><plain>Gene expression profiling (GEP) and miRNA expression profiling clearly differentiated pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, forming distinct clusters regardless of patient age </plain></SENT>
<SENT sid="3" pm="."><plain>However, pathway analysis of GEP data identified minor differences between corresponding pediatric and adult <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Predominance (6:1) of the germinal center B-cell subtype to activated B-cell subtype was found among pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Two cases were molecularly classified as primary mediastinal B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>We observed frequent abnormalities in 8q24 in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, including MYC rearrangement in 31% (5 of 16) and gain or amplification in 50% (6 of 12) nonrearranged cases </plain></SENT>
<SENT sid="7" pm="."><plain>MYC rearrangement was present in 96% (23 of 24) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases </plain></SENT>
<SENT sid="8" pm="."><plain>Array-based CGH analysis identified abnormalities that are shared between adult and pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (+12q15, +19q13, -6q), and abnormalities unique to the pediatric cases (-4p14, -19q13.32, +16p11.2), suggesting distinct pathogenetic mechanisms relative to age </plain></SENT>
<SENT sid="9" pm="."><plain>Elucidation of the underlying target genes may provide insight into factors that modulate outcome and could provide potential novel therapeutic targets with less toxicity for pediatric patients with B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>